Bank of America Corp DE Invests $54.06 Million in ICU Medical, Inc. $ICUI

Key Points

• Bank of America acquired a $54.06 million stake in ICU Medical during the second quarter, purchasing 368,754 shares and owning approximately 1.48% of the company. Institutional investors collectively hold 96.1% of ICUI’s outstanding shares.
• ICU Medical exceeded quarterly expectations, reporting $2.37 in EPS versus the $1.91 consensus estimate and $547.88 million in revenue. The company also maintained fiscal 2026 EPS guidance of $8.60–$9.00.
• Analyst sentiment remains positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $192.80, although company insiders sold about $3.91 million of shares over the past three months.

Bank of America Corp DE acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 368,754 shares of the medical instruments supplier's stock, valued at approximately $54,059,000. Bank of America Corp DE owned 1.48% of ICU Medical as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in ICUI. Man Group plc purchased a new stake in shares of ICU Medical during the 2nd quarter valued at approximately $595,000. Jupiter Topco LLC bought a new stake in shares of ICU Medical during the 2nd quarter valued at $407,786,000. Legal & General Group Plc bought a new stake in shares of ICU Medical during the 2nd quarter valued at $8,444,000. The Manufacturers Life Insurance Company purchased a new stake in ICU Medical during the 2nd quarter worth about $28,652,000. Finally, Cetera Trust Company N.A purchased a new stake in ICU Medical during the 2nd quarter worth about $328,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $152.65 on Monday. The stock's 50-day moving average is $168.30 and its 200 day moving average is $145.31. The stock has a market cap of $3.81 billion, a price-to-earnings ratio of 129.36, a P/E/G ratio of 1.93 and a beta of 0.75. ICU Medical, Inc. has a 1-year low of $112.50 and a 1-year high of $192.85. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to analysts' expectations of $533.44 million. During the same period last year, the business earned $2.10 earnings per share. The business's quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.

Insiders Place Their Bets

In other ICU Medical news, COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the transaction, the chief operating officer directly owned 37,377 shares of the company's stock, valued at $6,837,374.61. The trade was a 19.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elisha W. Finney sold 378 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the sale, the director owned 4,871 shares of the company's stock, valued at $888,860.08. The trade was a 7.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 21,830 shares of company stock valued at $3,905,003 over the last three months. 2.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of recent analyst reports. BTIG Research increased their price target on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Sanford C. Bernstein cut shares of ICU Medical to a "market perform" rating in a research note on Monday, June 15th. Zacks Research lowered shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Needham & Company LLC increased their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, Piper Sandler raised their price target on shares of ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, ICU Medical presently has an average rating of "Moderate Buy" and an average price target of $192.80.

ICU Medical Profile

ICU Medical, Inc develops, manufactures and sells medical devices used in infusion therapy, critical care and oncology. Its product portfolio includes infusion pumps, IV administration sets, needle-free connectors, vascular access devices, patient monitoring equipment and related accessories designed to support the delivery of fluids and medications and the monitoring of patients in healthcare settings.

The company also provides products for the safe handling of hazardous drugs, including closed-system transfer devices used in oncology and pharmacy operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.